Concourse Financial Group Securities, Inc. Allovir, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$0.7 - $0.82 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$0.72 - $0.82 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.64 - $0.78 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.68 - $2.39 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$2.15 - $3.64 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$2.15 - $3.64 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$3.17 - $5.82 $0 - $0
Q1 2023 May 15, 2023	BUY	$3.94 - $7.05 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$4.7 - $9.98 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$4.13 - $8.79 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$3.26 - $7.06 $0 - $0
Q1 2022 May 09, 2022	BUY	$6.75 - $13.52 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$12.94 - $25.99 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$16.97 - $25.06 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$19.44 - $25.06 $0 - $0
Q1 2021 May 13, 2021	BUY	$20.81 - $45.5 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$23.94 - $46.81 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$21.05 - $42.7 $0 - $0

Others Institutions Holding ALVR

# of Institutions

Shares Held

44.6M

Call Options Held

14.9K

Put Options Held

200

Eco R1 Capital, LLC San Francisco, CA

11.3M
Shares

$6.44 Million
0.4% of portfolio
Octagon Capital Advisors LP New York, NY

11.2M
Shares

$6.39 Million
2.19% of portfolio
Siren, L.L.C. New York, NY

6.6M
Shares

$3.76 Million
0.27% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.28M
Shares

$1.87 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.65M
Shares

$1.51 Million
0.0% of portfolio

View Full List

About Allovir, Inc.

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $53M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

More about ALVR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account